By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eisai Company, Ltd. 

4-6-10 Koishikawa, Bunkyo-ku

Tokyo    112-8088  Japan
Phone: 81-3-3817-3700 Fax: n/a


SEARCH JOBS


Key Statistics


Email: webmaster@eisai.co.jp
Ownership: Public

Web Site: Eisai Company
Employees: 7,043
Symbol: ESALY.PK
 





Collaborations

IDEC Pharma 

BioVeris Corporation 





Company News
Eisai Company (ESALY.PK) Release: Transfer Of Rights To Insomia Treatment / Anaesthesia Induction Agent Flunitrazepam In Japan 1/16/2017 11:35:00 AM
Eisai Company (ESALY.PK) Release: Pharma To Launch Medication Administration Support Device 1/12/2017 9:03:52 AM
Eisai Company (ESALY.PK) Release: Anticancer Agent Treakisym Approved In Japan For Additional Indication As First-Line Treatment For Low-Grade B-Cell Non-Hodgkin's Lymphoma And Mantle Cell Lymphoma 12/22/2016 12:56:15 PM
Eisai Company (ESALY.PK) And Keio University To Establish A New Industry-Academia Collaboration Site 12/22/2016 12:54:00 PM
Eisai Company (ESALY.PK) Release: Halaven (Eribulin) Receives Registration In South Africa For Treatment Of Women With Advanced Breast Cancer 12/1/2016 9:03:24 AM
Eisai Company (ESALY.PK) To Present Latest Data On Lenvatinib And Eribulin At ESMO Congress 2016 9/29/2016 9:11:49 AM
AbbVie (ABBV) And Eisai Company (ESALY.PK) Obtain Additional Approval For New Indication Of Fully Human Anti-TNF-Alpha Monoclonal Antibody HUMIRA In The Treatment Of Non-Infectious Uveitis 9/28/2016 9:34:34 AM
Eisai Company (ESALY.PK) Submits Supplemental Application For Partial Label Change For Antiepileptic Drug Fycompa 9/28/2016 9:07:37 AM
Eisai Company (ESALY.PK) Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 9/15/2016 11:19:53 AM
Eisai Company (ESALY.PK) Launches Ambitious 90-Scientist Collaborative R&D Unit in Boston Area 9/15/2016 6:07:53 AM
12345678910...
//-->